Drug Trial Radar · NCT05040126
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 7, 2021
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Tuberculosis Research Centre, IndiaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- International Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable Trust Hospital, Ghatkopar, Mumbai; Shatabdi Centenary Hospital, Govandi, Mumbai; King George's Medical College and Hospital, Lucknow; SN Medical College, Agra; Govt Medical College & Hospital, Bhavnagar; Govt. Medical College & Hospital, Surat; National Institute of Tuberculosis and Respiratory Diseases, New Delhi; Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, Delhi; Govt.Rajaji Medical college and hospital, Madurai
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models of care Reduction in direct costs and indirect costs of patients Improved treatment outcomes Need for shorter, tolerable and effective regimen Hence modified BPaL regimen is designed to study the newer shorter oral in varying doses of Linezolid for pre XDR Tb patients and MDR TI/NR patients
Conditions
- Pre-Extensively Drug-Resistant Pulmonary TB
- Treatment Intolerant Multidrug-Resistant Pulmonary TB
- Non-responsive Multidrug-Resistant Pulmonary TB
Interventions
LinezolidDrug
Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system. Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks. Participants will be followed for 48 weeks after the end of treatment
BedaquilineDrug
Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
PretomanidDrug
Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Treatment successTime frame: 12 months after successful TB treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
S N Medical College
Agra, Uttar Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.